Akebia is a fully integrated biopharmaceutical company focused on addressing complications associated with chronic kidney disease (CKD). The company is committed to advancing innovative therapies, particularly in the area of anemia related to CKD, which affects millions of patients in the U.S. Akebia's research and development efforts are centered around oral hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs). These innovative compounds are designed to mimic the body's natural response to low oxygen levels, thereby enhancing the production of erythropoietin (EPO) and improving red blood cell production. This approach aims to provide alternative treatment options for patients suffering from anemia due to CKD, addressing significant unmet medical needs.

In addition to its focus on anemia, Akebia emphasizes collaboration and partnership with healthcare professionals and researchers to further its clinical development initiatives. The company is actively engaged in expanding its pipeline of novel therapeutics through internal discovery and strategic collaborations. By leveraging its expertise in HIF biology and renal therapeutics, Akebia aims to make a meaningful impact on the lives of individuals affected by kidney disease, fostering a collaborative environment to drive scientific advancements in this critical area of healthcare.

United States

Since our founding in 2007, we’ve put tenacity and innovation to work to develop novel therapeutics that have the potential to set new standards of care for people living with kidney disease. We have emerged as a leader with deep roots in the renal community. Today, we are a fully integrated biopharmaceutical company with both an experienced nephrology-focused commercial team and a robust development organization. 

Kidney Diseases

Metabolic Diseases

Akebia

Anemia

Chronic kidney disease

Kidney disease

Vadadustat is an oral hypoxia-inducible factor (HIF) stabilizer currently in Phase 3 development for the treatment of anemia related to chronic kidney disease. Vadadustat exploits the same mechanism of action used by the body to adapt naturally to lower oxygen availability associated with a moderate increase in altitude. At higher altitudes, the body responds to lower oxygen availability with increased production of HIF, which coordinates the interdependent processes of iron mobilization and erythropoietin production to increase red blood cell production and, ultimately, improve oxygen delivery. Vadadustat is an investigational therapy not approved by the U.S. Food and Drug Administration or any regulatory authority.

Vafseo™ (Vadadustat)

Hyperphosphatemia

Upon swallowing AURYXIA, ferric iron is converted to ferrous iron by the enzyme ferric reductase in the gastrointestinal tract, where the molecules are absorbed in the same highly regulated physiological pathway as dietary iron.2,3,5,6 In the bloodstream, ferrous iron is oxidized back to ferric iron, which binds to transferrin, an iron transfer protein that transports iron to the bone marrow for incorporation into hemoglobin for RBC production.
<a href="https://www.auryxia.com/iron-deficiency-anemia/moa/">Source&nbsp;</a>

Akebia

Company Details